Abstract
Current review describes the prerequisites for clinical application of nuclear imaging with metaiodobenzylguanidine for cardiac sympathetic activity assessment. As the method developed, various quantitative parameters were proposed to evaluate its results. Some of them are still calculated and interpreted differently in various medical centers. This review systemizes the data regarding the attempts of method standardization, and describes factors that inhibit its validation for clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
